U.S. News & World Report Honors
7 SynCardia Certified Centers
Among "Best Children's Hospitals"
for Cardiology and Heart Surgery
Two Additional Top Children's Hospitals Ready to Perform 1st SynCardia Total Artificial Heart Implant
TUCSON, Ariz. – June 13, 2013 – SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that U.S. News & World Report has named seven SynCardia Certified Centers among the nation's "Best Children's Hospitals" for cardiology and heart surgery in its annual rankings for 2013-2014.
"The SynCardia temporary Total Artificial Heart has opened the flood gates in respect to the treatment possibilities for a quickly growing population of children in heart failure, including adolescents suffering from chronic rejection of their transplanted heart, end-stage heart failure accompanied by multiple congenital defects and a late-stage failing Fontan circulation," said Dr. David L.S. Morales, chief of pediatric cardiothoracic surgery at Cincinnati Children's Hospital Medical Center, which ranked in the top five.
SynCardia Certified Centers included in the list were:
- #2 Children's Hospital of Philadelphia (CHOP)
- #3 Texas Children's Hospital
- #5 Cincinnati Children's Hospital Medical Center
- #11 Children's Hospital of Wisconsin
- #26 Mattel Children's Hospital UCLA
- #32 Shands Hospital for Children at the University of Florida
- #34 Phoenix Children's Hospital
In addition to the seven hospitals listed above, #9 Lucile Packard Children's Hospital at Stanford and #43 Arkansas Children's Hospital have completed the first two phases of SynCardia's four-phase certification program and are ready to perform their first proctored implant once an appropriate patient has been identified.
Clinical research, surgical survival and ability to prevent bloodstream infections were among the factors making up 75% of the score used for the rankings. The other 25% reflects how many of 450 pediatric cardiologists and heart surgeons surveyed in 2011, 2012 and 2013 recommended the hospital.
CAUTION - The Freedom® portable driver is an investigational device, limited by United States law to investigational use.
SynCardia Systems, Inc. in Tucson, Arizona is the privately-held owner and manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart.
Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage biventricular heart failure in which both ventricles can no longer pump enough blood for a person to survive.
More than 1,350 implants of the SynCardia Total Artificial Heart accounts for over 400 patient years of life on the device. Since January 2011 more than 400 SynCardia Hearts have been implanted.
SynCardia Systems also manufactures the Freedom® portable driver, which powers the SynCardia Heart while allowing clinically stable patients to leave the hospital to live at home and in their communities. The wearable Freedom driver has been used by 190 patients, accounting for over 110 years of support.